Skip to main content
. 2019 Jul 27;21:179. doi: 10.1186/s13075-019-1960-5

Fig. 2.

Fig. 2

a Patients Global Assessment of Disease Activity (PGADA) assessed with a VAS evolution with time. b Comparison of the absolute difference of PGADA between T0 and T1 in the placebo and pooled low- and high-dose BCL groups. c Comparison of the absolute difference of PGDA between T0 and T3 in the placebo and pooled low- and high-dose BCL groups